Men who are sterile (including vasectomy confirmed by post vasectomy semen analysis) OR agree to use a condom with spermicide (refer to Section 2.6.1.3) and to not donate sperm during the study and for at least 180 days following last dose of TRC105 or pazopanib
The patient must agree not to donate sperm during the study treatment and for 3 months after receiving the last dose of study drug
Female patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)
Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)
Agree not to donate sperm until 6 months after the last dose of OPN-305
Male pts cannot donate semen or sperm while taking pomalidomide and for 28 days after completing the study.
During the study, and for 3 months after receiving the last dose of daratumumab, a woman must agree not to donate eggs (ova, oocytes) and men must agree not to donate sperm for the purposes of assisted reproduction
Agree to not donate semen or sperm for at least 12 months following the last dose of rituximab.
Male patients must agree to use a condom during treatment and for 90 days after dosing and must agree not to donate sperm for 90 days after dosing
Subjects must agree while on study drug and for 6 months following the last dose of study drug to:\r\n* Use a condom during sexual activity\r\n* Not donate sperm
Agree not to donate sperm during the course of this study or within 120 days after receiving their last dose of the study drugs.
Male patients must agree to use a condom during treatment and for 90 days after dosing and must agree not to donate sperm for 90 days after dosing
Patients must agree not to donate blood, sperm/ova during the course of taking protocol therapy and for at least 4 weeks after stopping treatment
Female patients who intend to donate eggs and male patients who intended to donate sperm during the course of this study or for 4 months after receiving the last dose of study treatment
Must agree not to donate sperm from first dose of study drug through 3 months after the last dose of study drug
Subjects (men and women) must agree to not donate sperm (males) or eggs (females) during and up to 120 days after the last dose of study treatment
Female patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)
Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)
Must agree not to donate sperm from the first dose of study drug to 105 days after the last dose of study drug.
Female patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)
Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)
Male patients must agree not to donate sperm during the study and for 2 months after discontinuation of vismodegib
Male subjects must not donate sperm from initial study drug administration, until 90 days after drug discontinuation.
Female patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)
Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)
222 Males who are unwilling to abstain from sperm donation while on study through 170 days after receiving the last dose of study drug.
Female patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)
Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)
A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study (including during dose interruptions), and for 4 weeks following discontinuation of lenalidomide, and if receiving daratumumab, for 3 months after the last dose
Agree not to donate sperm during the course of this study or within 120 days after receiving their last dose of study drug.
Female participants who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s).
Male participants who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s).
Man, who is sexually active with a woman of child-bearing potential and has not had a vasectomy, must agree to use an adequate contraception method as deemed appropriate by the Investigator, and must also agree to not donate sperm during the study and 3 months after last dose of daratumumab
A woman must agree to use an effective method of birth control and agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 3 months after receiving the last dose of study drug
Males must agree to abstain from donating blood, semen, or sperm during study participation and for at least 28 days after discontinuation from protocol treatment
Subject must agree not to donate sperm or ova from first dose of study drug through 3 months after the last dose of study drug.
Men must agree not to donate sperm during and after the study for 6 months after the last dose of bendamustine, 12 months after the last dose of rituximab, or 3 months after the last dose of study medication, whichever is later
Female patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)
Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)
Men must agree to not donate sperm during and after the study for 12 months after the last dose of rituximab or 3 months after the last dose of study drug, whichever is later
Agreement not to donate blood or blood products during the study and for at least 6 months after discontinuation of vemurafenib; for male partners, agreement not to donate sperm during the study and for at least 6 months after discontinuation of vemurafenib
Men must agree to use a double-barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study agent
For sexually active males, use of barrier form of contraception, even if they have had a vasectomy, during the study and for 6 months after stopping sonidegib is required; males should not donate sperm during treatment, and for up to six months after last dose
A man who is sexually active with a woman of childbearing potential must agree to use a barrier method of birth control during the study and for 4 weeks after receiving the last dose of study drug. All men must also not donate sperm during the study and for 90 days after receiving the last dose of study drug.
Must agree not to donate blood or semen as defined by the protocol
Agree to not donate semen during study drug therapy and for a period after end of study drug therapy.
Male subjects must not donate sperm during the Screening and Treatment periods, and for at least 3 months after the last dose of ALXN1007.
Males must agree not to donate semen or sperm for 3 months after last dose of CC-122.
Males must use adequate contraception and must not donate sperm for the duration of the study.
Female participants must agree to not donate eggs (ova) during the course of this study and for 30 days after receiving their last dose of TAK-117 and, for docetaxel, for as long as is mandated by local labeling.
Male participants must agree to not donate sperm during the course of the study and for 120 days after receiving their last dose of TAK-117 and, for docetaxel, for as long as is mandated by local labeling.
Male participants who intend to donate sperm during the course of this study or 120 days after receiving their last dose of TAK-117 and, for docetaxel, for as long as is mandated by local labeling.
Males must agree to use a condom with spermicide every time they have sex during the study and for 3 months after the last dose of study drug; they also must agree to not donate sperm during the study and for 3 months after the last dose of study drug
Males must agree not to donate semen or sperm for the duration of the study and for 3 months after the last dose of CC-122.
Male and female patients must agree not to donate sperm or eggs, respectively, from the first dose of study drug through 105 days and 45 days after the last dose of study drug, respectively.
Male patients must agree not to donate sperm during the study and for 3 months after discontinuation of vismodegib
Agreement not to donate blood or blood products or to donate sperm during the study and for at least 6 months after discontinuation of vemurafenib
Male patients must agree not to donate semen or sperm
Male patients must agree not to donate semen or sperm.
Must agree to not donate semen during study drug therapy and for a period after end of study drug therapy.
Female patients must agree (during the study and for 3 months after receiving the last dose of study agent, not to donate eggs (ova, oocytes) for the purposes of assisted reproduction
A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control e.g., either condom with spermicidals or partner with occlusive cap with spermicidals and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug
Male patients must agree not to donate sperm during the study and for 2 months after discontinuation of vismodegib
Subjects must agree to not donate blood, organs, sperm or semen, and egg cells for usage in other individuals as detailed in the protocol
During the study and for 3 months after receiving the last dose of daratumumab, a woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction
Is expecting to donate eggs or sperm from the time of consent through 90 days after the last dose of study drug
Male participants: Agree to use a reliable method of birth control and to not donate sperm during the study and for at least 12 weeks following last dose of study drug or country requirements, whichever is longer.
